1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Lot Riding On IGI’s Promising Trispecific Antibody For Myeloma

 
• By Anju Ghangurde

Ahead of ASH 2024, Ichnos Glenmark Innovation’s CEO outlines to Scrip the promising profile of the alliance’s early stage trispecific versus existing bispecific antibodies in relapsed/refractory multiple myeloma, including a significant overall response rate.

Cyril Konto, President and CEO, Ichnos Glenmark Innovation, • Source: Ichnos Glenmark Innovation

Ichnos Glenmark Innovation (IGI) has a lot at stake as it readies to present first-time data from the Phase I study of its T cell-engaging trispecific antibody (ISB 2001) at the upcoming American Society of Hematology (ASH) Annual Meeting in San Diego, CA.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Bristol’s Growth Plans Take A Hit As Cobenfy Fails As A Schizophrenia Add-On

 
• By Mandy Jackson

Cobenfy is approved as a monotherapy, but failed in the adjunctive setting when combined with generic atypical antipsychotics, giving BMS a second Phase III failure in two weeks.

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

Pipeline Watch: Eight Approvals And Three Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.

More from Therapy Areas

In Brief: DIOSynVax And ACM Biolabs To Develop Bird Flu Vaccine

 
• By Sushmita Panda

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.

In Brief: US FDA Rejects Regeneron’s Bid to Extend Eylea HD Dosing

 
• By Sushmita Panda

Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.